not tagged
not tagged
['cart,(-cartitude)', 'follicular', 'lymphoma']
updated phase 1/2 #data presented by at #eha2022 show a favorable safety profile, 94% overall response rate, 78% complete response rate for mb-106, a cd20-targeted, autologous #cartcell #therapy in #patients with follicular lymphoma. $mbio 
Mustang Bio, a Fortress Biotech company, is focused on the development of novel immunotherapies and gene therapies in areas of unmet need.